Do you need more information
MYCOPLASMA IST 3 combines enumeration, identification and antibiotic susceptibility testing for detection of Mycoplasma hominis and Ureaplasma spp.
Do you need more information
The increasing resistance of Ureaplasma spp. and M. hominis to current antibiotics requires the testing of new, better adapted antibiotics.
The MYCOPLASMA IST 3 strip enables the identification and enumeration of the Mycoplasma hominis and Ureaplasma spp. In addition, 6 antibiotics can be tested:
|
|
MYCOPLASMA IST 3 |
|
|
Ureaplasma spp. |
Mycoplasma hominis |
|
|
Erythromycin |
+ |
- |
|
Tetracycline |
+ |
+ |
|
Telithromycin |
+ |
- |
|
Levofloxacin |
+ |
+ |
|
Moxifloxacin |
+ |
+ |
|
Clindamycin |
- |
+ |
|
Doxycycline |
+ deduced |
+ deduced |
|
Azithromycin |
+ deduced |
- |
| NEW FEATURES | DIRECT BENEFITS |
| Validated on male urine and semen | Less invasive collection for improved patient comfort |
| Compatible with ESwab® for urethral, vaginal and cervical swabs | More applications |
| Includes all antibiotics recommended by the CLSI | Optimized preanalytical step |
| Improved sensitivity: threshold of 103 CFU/mL for Ureaplasma spp. for urine | Compliance with international guidelines |
| AST differenciated for mixed culture of Ureaplasma spp. and M. hominis | Improved pathogen detection |
| Large and robust clinical trials | Reliable guidance of antibiotherapy |
| Report in CFU/mL | Result standardization |
|
EVALUATION BY THREE
CLINICAL LABORATORIES
|
SAMPLES (n = 516) |
| • Cardiff (UK) | • 45% vaginal/cervical swabs |
| • Lyon (France) | • 11% urethral swabs |
| • Pancevo (Serbia) | • 17% semen |
| • 28% male urine |
| TEST 1: DETECTION AND IDENTIFICATION | ||
| Positive Agreement | Negative Agreement | |
| At the sample level |
97.5 [94.4-99.2]%
(199/204)
|
99.7 [98.2-100.0]%
(311/312)
|
|
At the species level
Ureaplasma spp.
|
98.5 [94.6-99.8]%
(129/131)
|
99.7 [98.6-100.0]%
(384/385)
|
|
At the species level
Mycoplasma hominis
|
92.6 [85.6-96.4]%
(88/95)
|
99.0 [97.5-99.7]%
(410/414)
|
| TEST 2: INDICATIVE ENUMERATION | ||
| Exact Agreement |
Within ± 101 CFU/ml
Agreement
|
|
| Combined species |
86.0 [80.3;90.3]%
(160/186)
|
97.8 [94.6;99.4]%
(182/186)
|
|
At the species level
Ureaplasma spp.
|
86.3 [78.9-91.4]%
(101/117)
|
100.0 [96.9-100.0]%
(117/117)
|
|
At the species level
Mycoplasma hominis
|
83.7 [74.5-90.0]%
(72/86)
|
94.2 [87.1;97.5]%
(81/86)
|
| TEST 3: ANTIMICROBIAL SUSCEPTIBILITY TESTING | ||||||
|
Ureaplasma
spp.
|
Isolates status (BMD) | Performance Index | ||||
| Total | #S | #R | CA | ME | VME | |
| Levofloxacin | 124 | 120 | 4 |
96.0%
(119/124)
|
4.2%
(5/120)
|
0 |
| Moxifloxacin | 124 | 123 | 1 |
98.4%
(122/124)
|
1.6%
(2/123)
|
0 |
| Tetracycline | 124 | 120 | 1 |
97.6%
(121/124)
|
1.7%
(2/120)
|
1 |
| Erythromycin | 124 | 120 | 4 |
99.2%
(123/124)
|
0.8%
(1/120)
|
0 |
| Telithromycin | 125 | 120 | 3 |
99.2%
(124/125)
|
0.8%
(1/122)
|
0 |
| All drugs combined | 621 | 605 | 16 |
98.1%
(609/621)
|
1.8%
(11/605)
|
1 |
| Mycoplasma hominis | Isolates status (BMD) | Performance Index | ||||
| Total | #S | #R | CA | ME | VME | |
| Levofloxacin | 84 | 82 | 2 |
98.8%
(83/84)
|
1.2%
(1/82)
|
0 |
| Moxifloxacin | 84 | 81 | 3 |
97.6%
(82/84)
|
1.2%
(1/81)
|
1 |
| Tetracycline | 84 | 65 | 19 |
97.6%
(82/84)
|
1.5%
(1/65)
|
1 |
| Clindamycin | 84 | 84 | 0 |
100.0%
(84/84)
|
0.0%
(0/84)
|
N/A |
| All drugs combined | 336 | 312 | 24 |
98.5%
(331/336)
|
1.0%
(3/312)
|
2 |
|
All drugs and
species combined
|
957 | 917 | 40 |
98.2%
(940/957)
|
1.5%
(14/917)
|
3 |
BMD : Broth MicroDilution / CA : Category Agreement / ME : Major Error / VME : Very Major Error
